COVID-19 Alters But Doesn’t Change M&A Machine In 2020
$12bn Viatris Merger Completes In Remarkable Year
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
